Neoleukin Therapeutics, Inc. — FY2022 Form 10-K
Company identification: The filing is for Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), not Neurogene Inc. It covers the fiscal year ended December 31, 2022; the filing was signed March 20, 2023. Accordingly, it is an annual report, not a standalone fourth-quarter report.
Business context and material developments
Neoleukin was developing immunotherapies using computationally designed “de novo” proteins, with a focus on cancer, inflammation, and autoimmunity. In November 2022, it decided to discontinue its lead candidate NL-201 and reduced its workforce by approximately 40%. NL-201’s Phase 1 trial, including a combination arm with pembrolizumab, was being wound down. The company cited its review of preliminary data, the expected benefit-risk balance, and developments in IL-2 therapeutics; the filing does not report a definitive full-trial efficacy result.
In March 2023, after year-end, the Board approved another restructuring: suspend research and development, reduce the remaining workforce by approximately 70%, and pursue strategic alternatives such as a sale, merger, asset divestiture, licensing transaction, or other deal. No transaction was assured. The company estimated $2.5–$3.0 million of related costs, mostly in the first half of 2023, and expected substantial completion by the end of the second quarter.
Financial results and liquidity
| Metric | FY2022 / Dec. 31, 2022 | FY2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $41.1 million | $39.2 million |
| General and administrative expense | $18.0 million | $21.5 million |
| Total operating expenses | $59.1 million | $60.7 million |
| Net loss | $57.6 million | $60.7 million |
| Net loss per share, basic and diluted | $1.04 | $1.10 |
| Cash used in operating activities | $45.6 million | $47.6 million |
| Cash, cash equivalents, and short-term investments | $96.4 million | $142.5 million in cash and cash equivalents; no short-term investments reported |
| Working capital | $88.1 million | Not stated in the provided filing text |
| Total liabilities | $21.6 million | $20.4 million |
Operating expenses fell 3% year over year: R&D increased 5%, largely reflecting NL-201 trial and restructuring costs, while G&A decreased 17%, primarily due to lower personnel costs. Interest income rose to $1.6 million from $19,000 as interest rates increased. There is no meaningful commercial gross margin disclosed because the company had no product sales. The company reported no conventional borrowings in the presented balance sheet; lease liabilities were $12.1 million, and undiscounted operating and finance lease commitments totaled $17.0 million.
Investing activities used $59.1 million, mainly reflecting purchases of available-for-sale securities net of maturities and equipment purchases. Financing activities provided $0.2 million. The decrease in cash and restricted cash during the year was $104.6 million, substantially reflecting the transfer of cash into short-term investments as well as operating use. The company stated that available capital was expected to fund operations for at least 12 months after filing, based on its then-current plan, which excluded restarting R&D or starting clinical trials.
Outlook, risks, and unusual items
- Outlook: No revenue or earnings guidance was provided. Management’s immediate focus was conserving cash and evaluating strategic alternatives; future funding needs and the outcome and timing of that process were uncertain.
- Business continuity and transaction risk: A strategic transaction may not occur or may not create value. The Board could instead pursue dissolution and liquidation; distributions, if any, would depend on timing and reserves for obligations and contingencies.
- Capital and listing risk: The company reported a Nasdaq minimum-bid-price deficiency notice received in October 2022, with an initial compliance deadline of April 24, 2023. Failure to regain compliance could lead to delisting and impair access to capital and share liquidity.
- Pipeline risk: NL-201 was discontinued, and the remaining programs were early-stage; R&D was subsequently suspended. No other candidate was in a clinical trial, and the company had no near-term plans to start one.
- Restructuring costs: The 2022 workforce reduction was expected to cost $1.8 million; $1.4 million was incurred in 2022 and $0.4 million remained. The separate March 2023 restructuring estimate was $2.5–$3.0 million.
- Lease commitments: Operating lease obligations were $16.5 million undiscounted, primarily for Seattle facilities, including a principal lease scheduled to expire in 2029. The company had sublet its additional 6,272-square-foot space through August 2023, with an extension option.
- Other risks: The filing highlights uncertainty around the unproven protein-design platform, clinical and regulatory outcomes, third-party manufacturing and supply, intellectual-property protection, financing, and retaining personnel needed for a strategic process.
- Audit and controls: Deloitte issued an unqualified opinion on the financial statements and reported no critical audit matters. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal control effectiveness.
Key facts investors should verify
- Whether the strategic-alternatives review resulted in a transaction, liquidation plan, or other outcome, and the expected timing and net value to shareholders.
- Cash, investments, spending, restructuring payments, and lease or other obligations in subsequent filings; the stated 12-month runway depended on the company’s then-current plan.
- Nasdaq listing compliance status and any reverse stock split or other action taken to address the bid-price deficiency.
- The final costs and completion status of both workforce reductions, including any additional liabilities or savings.
- The terms and continuing status of the University of Washington license, including potential payments if assets or the company are transferred.
- The share count and potential dilution: 42.65 million common shares were outstanding at year-end, and 12.66 million pre-funded warrants were also outstanding and included in the loss-per-share calculation.